First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2010-09-03 10:29:03Open Document File Size: 580,13 KBShare Result on FacebookCompanyMitsubishi / Eli Lilly / Johnson & Johnson / LG / Novartis / Japan Tobacco / Metabolex / Boehringer Ingelheim / Incyte / Roche / GlaxoSmithKline / Merck / Biodel / TransTech Pharma / AstraZeneca / Novo Nordisk / Bristol-Myers Squibb / Elite Pharmaceuticals Inc. / /ContinentNorth America / Europe / /CountryJapan / United States / /CurrencyUSD / /EventFDA Phase / Earnings Announcement / /FacilityNovo Nordisk’s pipeline / Diabetes Pipeline / /IndustryTermbiological products / Treatment of diabetes / non-recombinant products / established products / insulin products / combination products / modified insulin products / /MedicalConditionSummary Diabetes mellitus / obesity / hypersensitivity / II diabetes / highly prevalent disease / I diabetes / disease / hyperglycemia / diabetes / acute coronary syndrome / diabetes mellitus / autoimmune disease / /OrganizationFDA / /PositionExecutive / /ProductNovoLog / pioglitazone / Janumet / TGR5 / Byetta / Avandamet / Actoplus Met / Humalog / glimepiride / Lantus / Levemir / Prandin / repaglinide / Actos / Canagliflozin / Amaryl / Januvia / Avandia / rosiglitazone / GSK-184072 / MBX-2982 / TT-223 / VIAject / three / INCB-13739 / Europe / Japan / JTT-654 / Three oral / BI-10773 / GLP-1 / HSD1 / Phase II / GSK-1362885 / /URLwww.InsightPharmaReports.com / /SocialTag |